World TB Day: New Tests & Innovations to Accelerate TB Elimination | WHO

The World Health Organization (WHO) is calling for accelerated action to combat tuberculosis (TB), particularly through expanded access to innovative diagnostic tools. This push, timed with World TB Day on March 24th, focuses on bringing faster, more accessible testing to communities worldwide, and includes the leverage of recent methods like point-of-care tests and tongue swabs to detect the disease more rapidly.

Faster, Simpler TB Detection: A New Approach

New guidelines issued by the WHO detail tests that can be used near the point of care – meaning closer to where patients seek medical attention. These portable, user-friendly tests represent a significant step towards quicker diagnosis of one of the world’s most deadly infectious diseases. Importantly, they are available at less than half the cost of many existing molecular diagnostics, potentially expanding testing access in resource-limited settings. The tests as well operate on battery power and can deliver results in under an hour, allowing for faster initiation of treatment. “These new tools could be truly transformative for tuberculosis, by bringing speedy, accurate diagnosis closer to people, saving lives, curbing transmission and reducing costs,” stated Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. More details on the new guidelines are available on the WHO website.

Beyond TB specifically, these diagnostic devices hold promise for testing for other diseases, including HIV, mpox, and HPV. This broader application could lead to more patient-centered, equitable, and integrated healthcare services, particularly for emerging and circulating diseases.

Who is at Risk and How Does This Impact Them?

Tuberculosis disproportionately affects low- and middle-income countries, but remains a public health concern globally. Individuals living in crowded conditions, those with weakened immune systems (such as people living with HIV), and those with malnutrition are at higher risk of contracting TB. The WHO’s focus on expanding diagnostic access directly addresses the challenges faced by these vulnerable populations, who often experience delays in diagnosis and treatment. The new tongue swab method is particularly significant, as it allows for testing of adults and adolescents who are unable to produce sputum – a traditional requirement for TB diagnosis – potentially identifying cases that would otherwise be missed. This is crucial, as these individuals are at increased risk of dying from the disease.

Understanding the New Diagnostic Methods

Traditionally, TB diagnosis relies on analyzing sputum samples – mucus coughed up from the lungs. However, collecting sputum can be difficult for some patients. The WHO’s new guidelines recommend two innovative approaches to overcome this challenge. First, tongue swabs offer a less invasive and more accessible method for sample collection, particularly for those unable to produce sputum. Second, the guidelines advocate for sputum pooling, a cost-saving strategy where samples from multiple individuals are combined and tested together. This approach can significantly reduce the cost of testing and accelerate results, especially in settings with limited resources. Co-Diagnostics is shipping diagnostic materials to India to support clinical studies following these new guidelines.

The Importance of Investment and Research

While these new diagnostic tools are a major advancement, the WHO emphasizes that ending TB requires sustained investment in research and innovation. Global funding for TB research currently falls significantly short of the estimated annual necessitate of around US$5 billion. This funding gap hinders the development of new diagnostics, medicines, and vaccines essential for eradicating the epidemic. The WHO is actively working with partners through initiatives like the TB Vaccine Accelerator Council to accelerate the development and equitable access to new TB vaccines. This council aims to align governments, researchers, funders, and industry around shared priorities and coordinated investment.

What the Evidence Shows: Limitations and Considerations

The effectiveness of these new diagnostic tools will depend on several factors, including their implementation in diverse healthcare settings and their performance in real-world conditions. While the WHO guidelines are based on rigorous evaluation, ongoing monitoring and evaluation will be crucial to assess their impact and identify any challenges. It’s vital to remember that diagnostics are just one piece of the puzzle; successful TB control also requires effective treatment, prevention, and addressing the social and economic factors that contribute to the spread of the disease.

Looking Ahead: A Multi-faceted Approach

On World TB Day 2026, the WHO is urging countries and communities to prioritize several key actions. These include accelerating the rollout of new diagnostic technologies, strengthening people-centered TB care with community leadership, building resilient health systems, tackling the social and economic drivers of TB through multisectoral action, and protecting essential TB services during global crises and funding constraints. Dr. Tereza Kasaeva, Director of WHO’s Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, highlights that investing in TB is not only a health imperative but also a strategic political and economic choice, potentially yielding up to US$43 in health and economic returns for every dollar spent. Further information on the global TB effort can be found on the WHO news page.

As countries commemorate World TB Day, the WHO emphasizes the need for governments and partners to prioritize TB as a central component of health security and universal health coverage. Continued vigilance, investment, and collaboration will be essential to achieve the ambitious goal of ending TB globally.